These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 29772672)

  • 1. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
    Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
    Tee AR; Sampson JR; Pal DK; Bateman JM
    Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
    Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
    Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR signaling in neural stem cells: from basic biology to disease.
    Magri L; Galli R
    Cell Mol Life Sci; 2013 Aug; 70(16):2887-98. PubMed ID: 23124271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
    Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
    J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
    Jeong A; Wong M
    Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
    Wong M
    Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching on mTORC1 induces neurogenesis but not proliferation in neural stem cells of young mice.
    Mahoney C; Feliciano DM; Bordey A; Hartman NW
    Neurosci Lett; 2016 Feb; 614():112-8. PubMed ID: 26812181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
    Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
    Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous sclerosis--A model for tumour growth.
    Dodd KM; Dunlop EA
    Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
    Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
    J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
    Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
    Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
    Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
    Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
    Karalis V; Caval-Holme F; Bateup HS
    Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.